Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01327781 | Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY |
| 16 |
| Aug 25, 2026 |
| clinicaltrials |
| NCT07610148 | A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants | active not recruiting | Phase 1 | 21 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06590857 | Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.(TRACY-1) | active not recruiting | Phase 1 / Phase 2 | 16 | RayzeBio, Inc.INDUSTRY | 3 | Aug 24, 2026 | clinicaltrials |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | active not recruiting | Early Phase 1 | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04360941 | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer(PAveMenT) | active not recruiting | Phase 1 | 45 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 210 | Hoffmann-La RocheINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT01450020 | Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors | active not recruiting | N/A | 145 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02728076 | MRI-Based Preoperative Accelerated Partial Breast Irradiation | active not recruiting | N/A | 39 | Medical College of WisconsinOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04557449 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors(CDK4i) | active not recruiting | Phase 2 | 362 | PfizerINDUSTRY | 8 | Aug 20, 2026 | clinicaltrials |
| NCT04673448 | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05394259 | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | active not recruiting | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06027268 | Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer(ToPCourT) | active not recruiting | Phase 2 | 36 | Wake Forest University Health SciencesOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT01824745 | Survivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors | active not recruiting | N/A | 100 | City of Hope Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03959891 | AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) | active not recruiting | Phase 1 | 77 | Massachusetts General HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04383275 | Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)(IRIS) | active not recruiting | Phase 2 | 367 | Fudan UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04482244 | RCT of CBD for Anxiety in Advanced Breast Cancer | active not recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04550494 | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05069038 | Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy | active not recruiting | Phase 2 | 51 | University of NebraskaOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05975736 | Searching for Masses and Calcifications at the Same Time in Breast Cancer Screening | active not recruiting | N/A | 70 | Brigham and Women's HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03616587 | Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.(SERENA-1) | active not recruiting | Phase 1 | 396 | AstraZenecaINDUSTRY | 3 | Aug 18, 2026 | clinicaltrials |
| NCT06144944 | Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer | active not recruiting | Phase 3 | 160 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT01266642 | Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer | active not recruiting | Phase 2 | 301 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT02955940 | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | active not recruiting | Phase 2 | 10 | Incyte CorporationINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT03980054 | A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | active not recruiting | Phase 3 | 2,135 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05340673 | Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer | active not recruiting | Phase 1 | 208 | City of Hope Medical CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06635447 | Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients(CAPItrue) | active not recruiting | Phase 3 | 293 | AstraZenecaINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04855552 | Telehealth Weight Loss Program for Breast Cancer Survivors(TWL) | active not recruiting | N/A | 22 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT01937117 | Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer | active not recruiting | Phase 2 | 88 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03332797 | A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer | active not recruiting | Phase 1 | 181 | Genentech, Inc.INDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT03858322 | 'ADVANCE' (A Pilot Trial) | active not recruiting | Phase 1 | 41 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer(OPERA-01) | active not recruiting | Phase 3 | 510 | Olema Pharmaceuticals, Inc.INDUSTRY | 26 | Aug 13, 2026 | clinicaltrials |
| NCT06399757 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Apollo Therapeutics LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03696030 | HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases | active not recruiting | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04007770 | Acupuncture Pilot Study for Cancer-related Cognitive Function | active not recruiting | Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04267796 | Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women | active not recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05046301 | Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications | active not recruiting | — | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05931874 | Optimizing a mHealth Physical Activity Intervention With Mindful Awareness Lessons in Breast Cancer Survivors(F2TMind) | active not recruiting | N/A | 304 | Northwestern UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07761390 | DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction(DIEP-MDS) | active not recruiting | — | 1,500 | ZhulilingOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04739761 | A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer(DESTINY-B12) | active not recruiting | Phase 3 | 506 | AstraZenecaINDUSTRY | 18 | Aug 11, 2026 | clinicaltrials |
| NCT05056844 | Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge | active not recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05090358 | Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer | active not recruiting | Phase 2 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05113251 | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | active not recruiting | Phase 3 | 927 | AstraZenecaINDUSTRY | 18 | Aug 11, 2026 | clinicaltrials |
| NCT06680921 | A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) | active not recruiting | Phase 3 | 482 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT02564848 | Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65 | active not recruiting | N/A | 200 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05952557 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)(CAMBRIA-2) | active not recruiting | Phase 3 | 5,511 | AstraZenecaINDUSTRY | 44 | Aug 10, 2026 | clinicaltrials |
| NCT03408717 | Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery(B-CAPP) | active not recruiting | — | 220 | KK Women's and Children's HospitalOTHER_GOV | 2 | Aug 7, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 25, 2026source: clinicaltrials